Speed and Safety in Drug Discovery  Discussion meeting 26 November 2008 9am – 5pm The Royal Society 6-9 Carlton House Terrace, London SW1Y 5AG
Home Biogrophies Abstracts Presentations Links

Speakers' Abstracts


Prof Zvia Agur
Optimata Ltd., Ramat-Gan 52522, Israel; Institute for Medical BioMathematics (IMBM), Bene Ataroth, Israel.
Use of the Virtual Patient Technology to Improve Drug Safety: A Personalized Medicine Test Case

Dr Gregory T. Baxter, Hurel Corporation, HµREL Corporation
8840 Wilshire Boulevard, 2nd Floor
Beverly Hills, CA 90211, USA.
Hurel, An In Vivo Surrogate Assay Platform for Cell-Based Studies

Dr Robert A Coleman
Consultant
Drug Discovery and Development Tomorrow: Changing the Mindset

Prof Johannes Doehmer
BioProof AG, Weihenstephaner Str. 28, D-81673 München, Germany.
Use and Value of in vitro Technologies in Metabolism

Dr Mark Seymour
Xceleron Ltd, York Biocentre, Innovation Way, Heslington, York, YO10 5NY, UK.
The best model for humans is humans - how to accelerate early clinical development safely

Russell Higbee
VaxDesign, 12612 Challenger Pkwy. Orlando, FL 32826, USA.
A clinical trial in a test tube

Prof Chris Hillier
Glasgow Caledonian University, City Campus
70 Cowcaddens Rd, Glasgow, G4 0BA, UK.
Testing efficacy and sensitivity using small human isolated tissue

Prof Markus Müller
Vienna Medical University, Allgemeines Krankenhaus, Währinger Gürtel 18–20, A-1090 Vienna, Austria.
Monitoring tissue drug levels by microdialysis

Dr Paul Newbold
Global Head of Early Clinical Development, Respiratory & Inflammation Therapy Area, ASTRAZENECA.
Humanising Drug Discovery to Make Earlier & Better Stop/Go Decisions in Pharma R & D

Katya Tsaioun, Ph.D.
Apredica
ADDME – Avoiding Drug Development Mistakes Early

Dr Quin Wills,
Simugen Ltd, 2 Oakington Business Park, Dry Drayton Road,
Oakington, Cambridge, CB24 3DQ, UK.
The latest technologies to 'open up' and 'read' what's going on in cells